|Audit||Nominating and Governance||Compensation||Strategic|
|John T. Henderson, M.D.|
|Lawrence C. Best|
Chairman and Founder of OXO Capital LLC
Lawrence C. Best, a Director of the Company since September 2009, joined Boston Scientific Corporation in 1992 and served for 15 years as the Executive Vice President-Finance & Administration and Chief Financial Officer. Prior to joining Boston Scientific, Mr. Best was a partner in the accounting firm of Ernst & Young, where he specialized in serving multinational companies in the high technology and life sciences fields. He served a two-year fellowship at the SEC from 1979 to 1981 and a one-year term as a White House-appointed Presidential Exchange Executive in Washington, D.C. He currently serves on the Board of Directors of Haemonetics Corp. and is a founding director of the President's Council at Massachusetts General Hospital. Mr. Best received a B.B.A. degree from Kent State University.
|Heiner Dreismann, Ph.D.|
|Walter Gilbert, Ph.D.|
|Dennis Langer, M.D, J.D.|
|S. Louise Phanstiel|
Stock transaction information provided by EDGAR Online. Myriad Genetics, Inc. makes no representation or warranty with respect to any of the information contained herein, takes no responsibility for supplementing, updating or correcting any such information and shall have no liability with respect to any such information. This listing does not include derivatives, such as stock option grants or shares purchased through an employee stock purchase plan. For recent transactions, including derivative transactions, see our Section 16 SEC filings page.
Stock Quote (NASDAQ:MYGN)
Provided by eSignal.
Corporate Communications and Media Relations